Ophthalmic timolol: Plasma concentration and systemic cardiopulmonary effects

References

• Ulrych M., Franciosa J., Conway J. Comparison of a new beta adrenergic blocker (MK 950) and propranolol in man. Clin Pharmacol Ther 1972; 13: 232–8
   PubMed Web of Science ®Google Scholar
• Brazier D. J., Smith S. E. Ocular and cardiovascular response to topical carteolol 2 % and timolol 0.5 % in healthy volunteers. Br J Ophthalmol 1988; 72: 101–3
   PubMed Web of Science ®Google Scholar
• Neufeld A. H., Bartels S. P., Liu J. H. Laboratory and clinical studies on the mechanism of action of timolol. Surv Ophthalmol 1983; 28 Suppl: 286–92
   PubMedGoogle Scholar
• Waldock A., Snape J., Graham C. M. Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients. Br J Ophthalmol 2000; 84: 710–3
   PubMed Web of Science ®Google Scholar
• Doyle W. J., Weber P. A., Meeks R. H. Effect of topical timolol maleate on exercise performance. Arch Ophthalmol 1984; 102: 1517–8
   PubMed Web of Science ®Google Scholar
• Leier C. V., Baker N. D., Weber P. A. Cardiovascular effects of ophthalmic timolol. Ann Intern Med 1986; 104: 197–9
   PubMed Web of Science ®Google Scholar
• Dickstein K., Aarsland T. Comparison of the effects of aqueous and gellan ophthalmic timolol on peak exercise performance in middle‐aged men. Am J Ophthalmol 1996; 121: 367–71
   PubMed Web of Science ®Google Scholar
• Vuori M. L., Ali‐Melkkila T., Kaila T., Iisalo E., Saari K. M. Plasma and aqueous humor concentrations and systemic effects of topical betaxolol and timolol in man. Acta Ophthalmol (Copenh) 1993; 71: 201–6
   PubMed Web of Science ®Google Scholar
• Nino J., Tahvanainen K., Uusitalo H., Turjanmaa V., Hutri‐Kähönen N., Kaila T., et al. Cardiovascular effects of ophthalmic 0.5 % timolol aqueous solution and 0.1 % timolol hydrogel. Clin Physiol Funct Imaging 2002; 22: 271–8
   PubMed Web of Science ®Google Scholar
• Korte J. M., Kaila T., Saari K. M. Systemic bioavailability and cardiopulmonary effects of 0.5 % timolol eyedrops. Graefes Arch Clin Exp Ophthalmol 2002; 240: 430–5
   PubMed Web of Science ®Google Scholar
• Uusitalo H., Nino J., Tahvanainen K., Turjanmaa V., Ropo A., Tuominen J., et al. Efficacy and systemic side‐effects of topical 0.5 % timolol aqueous solution and 0.1 % timolol hydrogel. Acta Ophthalmol Scand 2005; 83: 723–8
   PubMedGoogle Scholar
• Uusitalo H., Kahonen M., Ropo A., Maenpaa J., Bjarnhall G., Hedenstrom H., et al. Improved systemic safety and risk‐benefit ratio of topical 0.1 % timolol hydrogel compared with 0.5 % timolol aqueous solution in the treatment of glaucoma. Graefes Arch Clin Exp Ophthalmol 2006; 244: 1491–6
   PubMed Web of Science ®Google Scholar
• Ingelman‐Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 2004; 25: 193–200
   PubMed Web of Science ®Google Scholar
• Siest G., Jeannesson E., Berrahmoune H., Maumus S., Marteau J. B., Mohr S., et al. Pharmacogenomics and drug response in cardiovascular disorders. Pharmacogenomics 2004; 5: 779–802
   PubMed Web of Science ®Google Scholar
• Shedden A. H., Laurence J., Barrish A., Olah T. V. Plasma timolol concentrations of timolol maleate: timolol gel‐forming solution (TIMOPTIC‐XE) once daily versus timolol maleate ophthalmic solution twice daily. Doc Ophthalmol 2001; 103: 73–9
   PubMedGoogle Scholar
• Urtti A. Delivery of antiglaucoma drugs: ocular vs systemic absorption. J Ocul Pharmacol 1994; 10: 349–57
   PubMedGoogle Scholar
• Vuori M. L., Kaila T. Plasma kinetics and antagonist activity of topical ocular timolol in elderly patients. Graefes Arch Clin Exp Ophthalmol 1995; 233: 131–4
   PubMed Web of Science ®Google Scholar
• Dickstein K., Hapnes R., Aarsland T., Kristianson K., Viksmoen L. Comparison of topical timolol vs betaxolol on cardiopulmonary exercise performance in healthy volunteers. Acta Ophthalmol (Copenh) 1988; 66: 463–6
   PubMed Web of Science ®Google Scholar
• Umetsuki M. H., Kotegawa T., Nakamura K., Nakano S., Nakatsuka K. Temporal variation in the effects of ophthalmic timolol on cardiovascular and respiratory functions in healthy men. J Clin Pharmacol 1997; 37: 58–63
   PubMed Web of Science ®Google Scholar
• Stewart W. C., Cate E. A., Stewart J. A. Systemic beta‐blockade with once daily betimol or timoptic‐XE. J Ocul Pharmacol Ther 1999; 15: 225–31
   PubMed Web of Science ®Google Scholar
• Stewart W. C., Stewart J. A., Crockett S., Kubilus C., Brown A., Shams N. Comparison of the cardiovascular effects of unoprostone 0.15 %, timolol 0.5 % and placebo in healthy adults during exercise using a treadmill test. Acta Ophthalmol Scand 2002; 80: 272–6
   PubMedGoogle Scholar
• Stewart W. C., Stewart J. A., Jackson A. L. Cardiovascular effects of timolol maleate, brimonidine or brimonidine/timolol maleate in concomitant therapy. Acta Ophthalmol Scand 2002; 80: 277–81
   PubMedGoogle Scholar
• Ohno Y., Iga T., Yamada Y., Nagahara M., Araie M., Takayanagi R. Pharmacokinetic and pharmacodynamic analysis of systemic effect of topically applied timolol maleate ophthalmic gelling vehicle (Rysmon TG). Curr Eye Res 2005; 30: 319–28
   PubMed Web of Science ®Google Scholar
• Dickstein K., Hapnes R., Aarsland T. Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24‐hour heart rate response in patients on treatment for glaucoma. Am J Ophthalmol 2001; 132: 626–32
   PubMed Web of Science ®Google Scholar
• Diggory P., Cassels‐Brown A., Vail A., Hillman J. S. Randomised, controlled trial of spirometric changes in elderly people receiving timolol or betaxolol as initial treatment for glaucoma. Br J Ophthalmol 1998; 82: 146–9
   PubMed Web of Science ®Google Scholar
• Hayreh S. S., Podhajsky P., Zimmerman M. B. Beta‐blocker eyedrops and nocturnal arterial hypotension. Am J Ophthalmol 1999; 128: 301–9
   PubMed Web of Science ®Google Scholar
• Takahashi N., Iwasaka T., Sugiura T., Onoyama H., Kurihara S., Inada M., et al. Effect of coenzyme Q10 on hemodynamic response to ocular timolol. J Cardiovasc Pharmacol 1989; 14: 462–8
   PubMed Web of Science ®Google Scholar
• Stewart W. C., Day D. G., Holmes K. T., Stewart J. A. Effect of timolol 0.5 % gel and solution on pulmonary function in older glaucoma patients. J Glaucoma 2001; 10: 227–32
   PubMed Web of Science ®Google Scholar
• Fraunfelder F. T., Barker A. F. Respiratory effects of timolol. N Engl J Med 1984; 311: 1441
   PubMed Web of Science ®Google Scholar
• Wilson T. W., Firor W. B., Johnson G. E., Holmes G. I., Tsianco M. C., Huber P. B., et al. Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade. Clin Pharmacol Ther 1982; 32: 676–85
   PubMed Web of Science ®Google Scholar
• Zineh I., Beitelshees A. L., Gaedigk A., Walker J. R., Pauly D. F., Eberst K., et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 2004; 76: 536–44
   PubMed Web of Science ®Google Scholar
• Nieminen T., Uusitalo H., Turjanmaa V., Bjärnhall G., Hedenström H., Maenpää J., et al. Association between low plasma levels of ophthalmic timolol and haemodynamics in glaucoma patients. Eur J Clin Pharmacol 2005; 61: 369–74
   PubMed Web of Science ®Google Scholar
• Fourtillan J. B., Courtois P., Lefebvre M. A., Girault J. Pharmacokinetics of oral timolol studied by mass fragmentography. Eur J Clin Pharmacol 1981; 19: 193–6
   PubMed Web of Science ®Google Scholar
• Lohmoller G., Frohlich E. D. A comparison of timolol and propranolol in essential hypertension. Am Heart J 1975; 89: 437–42
   PubMed Web of Science ®Google Scholar
• Brogden R. N., Speight T. M., Avery G. S. Timolol: a preliminary report of its pharmacological properties and therapeutic efficacy in angina and hypertension. Drugs 1975; 9: 164–77
   PubMed Web of Science ®Google Scholar
• McGourty J. C., Silas J. H., Fleming J. J., McBurney A., Ward J. W. Pharmacokinetics and beta‐blocking effects of timolol in poor and extensive metabolizers of debrisoquin. Clin Pharmacol Ther 1985; 38: 409–13
   PubMed Web of Science ®Google Scholar
• Lennard M. S., Lewis R. V., Brawn L. A., Tucker G. T., Ramsay L. E., Jackson P. R., et al. Timolol metabolism and debrisoquine oxidation polymorphism: a population study. Br J Clin Pharmacol 1989; 27: 429–34
   PubMed Web of Science ®Google Scholar
• Huupponen R., Kaila T., Lahdes K., Salminen L., Iisalo E. Systemic absorption of ocular timolol in poor and extensive metabolizers of debrisoquine. J Ocul Pharmacol 1991; 7: 183–7
   PubMedGoogle Scholar
• Edeki T. I., He H., Wood A. J. Pharmacogenetic explanation for excessive beta‐blockade following timolol eye drops. Potential for oral‐ophthalmic drug interaction. JAMA 1995; 274: 1611–3
   PubMed Web of Science ®Google Scholar
• Nieminen T., Uusitalo H., Mäenpää J., Turjanmaa V., Rane A., Lundgren S., et al. Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. Eur J Clin Pharmacol 2005; 61: 811–9
   PubMed Web of Science ®Google Scholar
• Richerson G. B. The autonomic nervous system. Medical physiology a cellular and molecular approach: 2003; 99378–98, In: Boron W. F, Be L, eds. Philadelphia. Saunders
   Google Scholar
• Hoffman B. B., Taylor P. The autonomic and somatic motor nervous systems. Goodman & Gilman's the pharmacological basis of therapeutics, J. G Hardman, L. E Limbird. McGraw‐Hill, New York 2001; 115–53
   Google Scholar
• Atkins J. M., Pugh B. R, Jr., Timewell R. M. Cardiovascular effects of topical beta‐blockers during exercise. Am J Ophthalmol 1985; 99: 173–5
   PubMed Web of Science ®Google Scholar